SV2002000527A - USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS REF. READ 34714-SV - Google Patents

USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS REF. READ 34714-SV

Info

Publication number
SV2002000527A
SV2002000527A SV2001000527A SV2001000527A SV2002000527A SV 2002000527 A SV2002000527 A SV 2002000527A SV 2001000527 A SV2001000527 A SV 2001000527A SV 2001000527 A SV2001000527 A SV 2001000527A SV 2002000527 A SV2002000527 A SV 2002000527A
Authority
SV
El Salvador
Prior art keywords
vapes
ref
read
organ fibrosis
parapoxvirus ovis
Prior art date
Application number
SV2001000527A
Other languages
Spanish (es)
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV2002000527A publication Critical patent/SV2002000527A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a medicament having a preventive or curative effect on organ fibrosis in humans.SOLUTION: The medicament shows the effect to a common final path to all diseases connected to fibrosis, using the fact that a preparation of parapoxviruses, obtained from the strains D 1701, orf-11, Greek orf strain 176, Greek orf strain 155, and the New Zealand (NZ) strains inhibit transformation of hepatic stellate cells into collagen producing-myofibroblast type.
SV2001000527A 2000-07-11 2001-07-11 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS REF. READ 34714-SV SV2002000527A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (en) 2000-07-11 2001-05-08 Use of strains of the Parapoxvirus ovis against organ fibrosis

Publications (1)

Publication Number Publication Date
SV2002000527A true SV2002000527A (en) 2002-10-24

Family

ID=7648485

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000527A SV2002000527A (en) 2000-07-11 2001-07-11 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS REF. READ 34714-SV

Country Status (14)

Country Link
JP (2) JP5587950B2 (en)
KR (1) KR100845643B1 (en)
CN (1) CN101444539B (en)
AT (1) ATE445413T1 (en)
BR (1) BRPI0112411B8 (en)
DE (2) DE10122233A1 (en)
DK (1) DK1303302T3 (en)
DO (1) DOP2001000210A (en)
EC (1) ECSP034420A (en)
ES (1) ES2332355T3 (en)
PE (1) PE20020218A1 (en)
PT (1) PT1303302E (en)
SV (1) SV2002000527A (en)
ZA (1) ZA200300276B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (en) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Recombinant Orf virus vector
JP6875745B2 (en) * 2016-02-16 2021-05-26 国立大学法人大阪大学 Pharmaceutical composition for treating fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (en) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals
DK0885013T3 (en) * 1996-04-15 2001-11-05 Anton Prof Dr Med Vet Dr Mayr Use of multipotent paramuncture inducers from attenuated, non-immunogenic pox virus or parapox virus for the manufacture of drugs

Also Published As

Publication number Publication date
ES2332355T3 (en) 2010-02-03
BR0112411A (en) 2003-05-27
JP2014196329A (en) 2014-10-16
JP5950964B2 (en) 2016-07-13
BRPI0112411B8 (en) 2021-05-25
KR100845643B1 (en) 2008-07-10
KR20030019562A (en) 2003-03-06
DE50115181D1 (en) 2009-11-26
DOP2001000210A (en) 2002-12-15
DE10122233A1 (en) 2002-01-24
PT1303302E (en) 2009-11-11
ZA200300276B (en) 2004-04-13
JP2012214492A (en) 2012-11-08
CN101444539B (en) 2016-07-06
ECSP034420A (en) 2003-03-10
DK1303302T3 (en) 2010-02-08
BRPI0112411B1 (en) 2018-02-27
CN101444539A (en) 2009-06-03
ATE445413T1 (en) 2009-10-15
PE20020218A1 (en) 2002-05-19
JP5587950B2 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
Wu et al. Evaluation of tyrosinase inhibitory, antioxidant, antimicrobial, and antiaging activities of Magnolia officinalis extracts after Aspergillus niger fermentation
DK0693281T3 (en) Pharmaceutical Fluoxetine Formulations
MY144292A (en) Method of reducing oral tissue inflammation using magnolia extract
IL158559A (en) Use of 5-lipoxygenase inhibitors for the preparation of a pharmaceutical composition for treating acne
WO2003032941A3 (en) Cosmetic and/or dermatological active ingredient combination
TR200200725T2 (en) Anionic amino acid based surfactants.
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
ATE256392T1 (en) USE OF POLYAMINO ACID DERIVATIVES AS PRESERVATIVES
HUP0200152A2 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
ES2023848B3 (en) AGENTS TO REVITALIZE, STIMULATE AND STRENGTHEN HAIR GROWTH.
ES2127613T3 (en) USE OF A TNF-ALPHA ANTAGONIST FOR THE TREATMENT OF CUTANEOUS REDDES OF NEUROGENOUS ORIGIN.
SV2002000527A (en) USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS REF. READ 34714-SV
AU2309102A (en) Dermatological formulations
DE60006788D1 (en) IOD PRODUCTION COMPOSITION
AU5487101A (en) Cosmetic or dermatological product comprising a freeze-dried hydrocolloid composition
NO20052960L (en) Use of docosahexaenoic acid as an active substance for the treatment of lipodystrophy
TR200200724T2 (en) Use of fatty acid / amino acid soaps to increase the antimicrobial effect of pharmaceutical compositions that can be applied to the skin
Dartsch The potential of Asparagus‐P® to inactivate reactive oxygen radicals
EP1038529A3 (en) Agent for increasing chemokine production
Shaffrathul et al. Turmeric: Role in hypertrichosis and acne
WO2022169336A3 (en) Pharmaceutical composition for prevention or treatment of fibrosis comprising leuconostoc citreum strain as active ingredient
Fox Stop Trying Too Hard to Kill Bacteria
Baishya Topical ketoconazole therapy in a recalcitrant case of seborrhoeic dermatitis
Verheugt Differential dose effect of aspirin in the primary prevention of myocardial infarction
천현자 et al. Butyl Alcohol Extract from Caesalpinia sappan L Regulates Melanogenesis in B16/F10 Melanoma Cells

Legal Events

Date Code Title Description
FD Lapse